Kakizaki Fumihiko, Sonoshita Masahiro, Miyoshi Hiroyuki, Itatani Yoshiro, Ito Shinji, Kawada Kenji, Sakai Yoshiharu, Taketo M Mark
Department of Pharmacology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Division of Experimental Therapeutics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Cancer Sci. 2016 Nov;107(11):1622-1631. doi: 10.1111/cas.13063.
We recently found that the product of the AES gene functions as a metastasis suppressor of colorectal cancer (CRC) in both humans and mice. Expression of amino-terminal enhancer of split (AES) protein is significantly decreased in liver metastatic lesions compared with primary colon tumors. To investigate its downregulation mechanism in metastases, we searched for transcriptional regulators of AES in human CRC and found that its expression is reduced mainly by transcriptional dysregulation and, in some cases, by additional haploidization of its coding gene. The AES promoter-enhancer is in a typical CpG island, and contains a Yin-Yang transcription factor recognition sequence (YY element). In human epithelial cells of normal colon and primary tumors, transcription factor YY2, a member of the YY family, binds directly to the YY element, and stimulates expression of AES. In a transplantation mouse model of liver metastases, however, expression of Yy2 (and therefore of Aes) is downregulated. In human CRC metastases to the liver, the levels of AES protein are correlated with those of YY2. In addition, we noticed copy-number reduction for the AES coding gene in chromosome 19p13.3 in 12% (5/42) of human CRC cell lines. We excluded other mechanisms such as point or indel mutations in the coding or regulatory regions of the AES gene, CpG methylation in the AES promoter enhancer, expression of microRNAs, and chromatin histone modifications. These results indicate that Aes may belong to a novel family of metastasis suppressors with a CpG-island promoter enhancer, and it is regulated transcriptionally.
我们最近发现,AES基因的产物在人类和小鼠中均作为结直肠癌(CRC)的转移抑制因子发挥作用。与原发性结肠肿瘤相比,肝转移灶中分裂型氨基末端增强子(AES)蛋白的表达显著降低。为了研究其在转移过程中的下调机制,我们在人类CRC中寻找AES的转录调节因子,发现其表达主要通过转录失调而降低,在某些情况下,还通过其编码基因的额外单倍体化而降低。AES启动子-增强子位于典型的CpG岛中,并包含一个阴阳转录因子识别序列(YY元件)。在正常结肠和原发性肿瘤的人类上皮细胞中,YY家族成员转录因子YY2直接与YY元件结合,并刺激AES的表达。然而,在肝转移的移植小鼠模型中,Yy2(因此也是Aes)的表达下调。在人类CRC肝转移中,AES蛋白水平与YY2水平相关。此外,我们注意到在12%(5/42)的人类CRC细胞系中,19号染色体p13.3上AES编码基因的拷贝数减少。我们排除了其他机制,如AES基因编码或调控区域的点突变或插入缺失突变、AES启动子增强子中的CpG甲基化、微小RNA的表达以及染色质组蛋白修饰。这些结果表明,Aes可能属于一个具有CpG岛启动子增强子的新型转移抑制因子家族,并且它受到转录调控。